Skip to content

Source filing unavailable

Q2 2017 · —
Revenue$249.00Kno prior Q2 2016 on file+77.9% vs Q1 2017
Net Income-$9.17MN/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$36.21N/M vs Q2 2016N/M vs Q1 2017
Operating Income-$10,165,000—
Operating Cash Flowderived-$8,877,000—
Margins · derived
Operating margin-4082.3%
Net margin-3682.3%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2017Q2 2016
Revenue$249.00K—
Net Income-$9.17M-$6.06M
EPS Diluted-$36.21-$25.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR